Phase 1 Clinical Research Facility

With a state-of-the-art 120-bed Phase 1 facility and eight central nervous system focused research centers within a single organization, CNS provides a new model for improving the efficiency of early development while maintaining high-quality and scientific vigilance in these initial explorations of the potential of new therapeutics. As our experts in academic psychiatry collaboratively create custom development options with our clients, CNS’ experts in clinical psychiatry research add practical execution insights and gain from the healthy volunteer experience of a particular compound from their Comprehensive Phase One colleagues.

Strategic Expertise
CNS’ experts, coupled with their extensive relationships across academia, pharmaceutical companies, and government agencies, create an important advantage in interpreting regulatory advice, as well as scientific and safety findings. CNS’ internal and external associations can support sponsors in preparing for and conducting FDA and Advisory Board interactions, and working through the inevitable clinical flexibility required to bring central nervous system compounds through the development process.

Operational Integration
CNS’ Collaborative Centralization imperative enables research centers to enact practical solutions in areas of known inefficiency. These include centralized research center budgeting and contracting, regulatory approval (IRB) and quality (QA) processes, protocol and CRF design, as well as patient recruitment and retention.

Superior Partnership: Communication and Accountability
CNS’ integration supports teamwork without silos across scientific, medical, project management, regulatory, clinical conduct, biostatistics, and data management. CNS’ size allows for flexibility and rapid responsiveness in providing high-quality advice, communication, and dependability.